A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02880462 |
Recruitment Status :
Completed
First Posted : August 26, 2016
Last Update Posted : March 24, 2020
|
Tracking Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | August 15, 2016 | ||||||||||||
First Posted Date ICMJE | August 26, 2016 | ||||||||||||
Last Update Posted Date | March 24, 2020 | ||||||||||||
Actual Study Start Date ICMJE | December 26, 2016 | ||||||||||||
Actual Primary Completion Date | May 20, 2019 (Final data collection date for primary outcome measure) | ||||||||||||
Current Primary Outcome Measures ICMJE |
Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score [ Time Frame: 24 weeks ] The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure.
|
||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||
Change History | |||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||
Descriptive Information | |||||||||||||
Brief Title ICMJE | A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia | ||||||||||||
Official Title ICMJE | Phase 2 Study of the Effect of add-on Sulforaphane in Treatment of Schizophrenia | ||||||||||||
Brief Summary | The goal of the study is to investigate whether adding different doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons. |
||||||||||||
Detailed Description | This study will be carried out in six mental health institutes in China and total of 180 patients with first-episode or early onset schizophrenia will be enrolled into the study. The mental health institute at the Second Xiangya Hospital, Central South University. Individuals who participate in the study will be followed for 24 weeks. The changes in clinical symptoms and neurocognitive function will be assessed from baseline (week-2) to week-6 (acute phase), and week-12 to week-24 (maintenance phase). |
||||||||||||
Study Type ICMJE | Interventional | ||||||||||||
Study Phase ICMJE | Phase 2 | ||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan. Primary Purpose: Treatment
|
||||||||||||
Condition ICMJE | Schizophrenia | ||||||||||||
Intervention ICMJE |
|
||||||||||||
Study Arms ICMJE |
|
||||||||||||
Publications * |
|
||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||
Recruitment Information | |||||||||||||
Recruitment Status ICMJE | Completed | ||||||||||||
Actual Enrollment ICMJE |
172 | ||||||||||||
Original Estimated Enrollment ICMJE |
180 | ||||||||||||
Actual Study Completion Date ICMJE | May 20, 2019 | ||||||||||||
Actual Primary Completion Date | May 20, 2019 (Final data collection date for primary outcome measure) | ||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||
Sex/Gender ICMJE |
|
||||||||||||
Ages ICMJE | 18 Years to 50 Years (Adult) | ||||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||
Listed Location Countries ICMJE | Not Provided | ||||||||||||
Removed Location Countries | |||||||||||||
Administrative Information | |||||||||||||
NCT Number ICMJE | NCT02880462 | ||||||||||||
Other Study ID Numbers ICMJE | Stanley-Sulforaphane | ||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||
Current Responsible Party | Renrong Wu, Central South University | ||||||||||||
Original Responsible Party | Same as current | ||||||||||||
Current Study Sponsor ICMJE | Central South University | ||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||
Collaborators ICMJE | Stanley Medical Research Institute | ||||||||||||
Investigators ICMJE |
|
||||||||||||
PRS Account | Central South University | ||||||||||||
Verification Date | March 2020 | ||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |